Patent foramen ovale closure versus medical therapy for stroke prevention: A systematic review and meta-analysis of randomized controlled trials [version 2; referees: 2 approved]
Background: Previous randomized trials on patent foramen ovale (PFO) closure versus medical therapy for stroke prevention were inconclusive. Recently, two new randomized trials and new findings from an extended follow-up of a previous trial have been published on this topic. We conducted a systemati...
Main Authors: | , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
F1000 Research Ltd
2018-09-01
|
Series: | F1000Research |
Subjects: | |
Online Access: | https://f1000research.com/articles/6-2178/v2 |
id |
doaj-225f8cca90b14c80957f4de2ef6efe44 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jenny Chi Ling Lai Gary Tse William K.K. Wu Mengqi Gong George Bazoukis Wing Tak Wong Sunny Hei Wong Konstantinos Lampropoulos Adrian Baranchuk Lap Ah Tse Yunlong Xia Guangping Li Martin C.S. Wong Yat Sun Chan Nan Mu Mei Dong Tong Liu International Health Informatics Study (IHIS) Network |
spellingShingle |
Jenny Chi Ling Lai Gary Tse William K.K. Wu Mengqi Gong George Bazoukis Wing Tak Wong Sunny Hei Wong Konstantinos Lampropoulos Adrian Baranchuk Lap Ah Tse Yunlong Xia Guangping Li Martin C.S. Wong Yat Sun Chan Nan Mu Mei Dong Tong Liu International Health Informatics Study (IHIS) Network Patent foramen ovale closure versus medical therapy for stroke prevention: A systematic review and meta-analysis of randomized controlled trials [version 2; referees: 2 approved] F1000Research Cerebrovascular Disease Congenital Heart Disease |
author_facet |
Jenny Chi Ling Lai Gary Tse William K.K. Wu Mengqi Gong George Bazoukis Wing Tak Wong Sunny Hei Wong Konstantinos Lampropoulos Adrian Baranchuk Lap Ah Tse Yunlong Xia Guangping Li Martin C.S. Wong Yat Sun Chan Nan Mu Mei Dong Tong Liu International Health Informatics Study (IHIS) Network |
author_sort |
Jenny Chi Ling Lai |
title |
Patent foramen ovale closure versus medical therapy for stroke prevention: A systematic review and meta-analysis of randomized controlled trials [version 2; referees: 2 approved] |
title_short |
Patent foramen ovale closure versus medical therapy for stroke prevention: A systematic review and meta-analysis of randomized controlled trials [version 2; referees: 2 approved] |
title_full |
Patent foramen ovale closure versus medical therapy for stroke prevention: A systematic review and meta-analysis of randomized controlled trials [version 2; referees: 2 approved] |
title_fullStr |
Patent foramen ovale closure versus medical therapy for stroke prevention: A systematic review and meta-analysis of randomized controlled trials [version 2; referees: 2 approved] |
title_full_unstemmed |
Patent foramen ovale closure versus medical therapy for stroke prevention: A systematic review and meta-analysis of randomized controlled trials [version 2; referees: 2 approved] |
title_sort |
patent foramen ovale closure versus medical therapy for stroke prevention: a systematic review and meta-analysis of randomized controlled trials [version 2; referees: 2 approved] |
publisher |
F1000 Research Ltd |
series |
F1000Research |
issn |
2046-1402 |
publishDate |
2018-09-01 |
description |
Background: Previous randomized trials on patent foramen ovale (PFO) closure versus medical therapy for stroke prevention were inconclusive. Recently, two new randomized trials and new findings from an extended follow-up of a previous trial have been published on this topic. We conducted a systematic review and meta-analysis of randomized trials comparing PFO closure with medical therapy for stroke prevention. Methods: PubMed and Cochrane Library were searched until 16th September 2017. The following search terms were used for PubMed: "patent foramen ovale" AND (stroke OR embolism) and "randomized" AND "Trial". For Cochrane Library, the following terms were used: "patent foramen ovale" AND "closure" AND (stroke OR embolism). Results: A total of 91 and 55 entries were retrieved from each database using our search strategy respectively, of which six studies on five trials met the inclusion criteria. This meta-analysis included 1829 patients in the PFO closure arm (mean age: 45.3 years; 54% male) and 1972 patients in the medical therapy arm (mean age: 45.1 years; 51% male). The median follow-up duration was 50 ± 30 months. When compared to medical therapy, PFO closure significantly reduced primary endpoint events with a risk ratio [RR] of 0.60 (95% CI: 0.44-0.83, P < 0.0001; I2: 15%). It also reduced stroke (RR: 0.50, 95% CI: 0.35-0.73, P < 0.0001; I2: 32%) despite increasing the risk of atrial fibrillation/flutter (RR: 1.90, 95% CI: 1.23-2.93, P < 0.01; I2: 43%). However, it did not reduce transient ischemic accident events (0.75; 95% CI: 0.51-1.10, P = 0.14; I2: 0%), all-cause bleeding (RR: 0.89; 95% CI: 0.44-1.78, P = 0.74; I2: 51%) or gastrointestinal complications (RR: 0.92; 95% CI: 0.32-2.70, P = 0.88; I2: 0%). Conclusions: PFO closure significantly reduces risk of stroke when compared to medical treatment and should therefore be considered for stroke prevention in PFO patients. |
topic |
Cerebrovascular Disease Congenital Heart Disease |
url |
https://f1000research.com/articles/6-2178/v2 |
work_keys_str_mv |
AT jennychilinglai patentforamenovaleclosureversusmedicaltherapyforstrokepreventionasystematicreviewandmetaanalysisofrandomizedcontrolledtrialsversion2referees2approved AT garytse patentforamenovaleclosureversusmedicaltherapyforstrokepreventionasystematicreviewandmetaanalysisofrandomizedcontrolledtrialsversion2referees2approved AT williamkkwu patentforamenovaleclosureversusmedicaltherapyforstrokepreventionasystematicreviewandmetaanalysisofrandomizedcontrolledtrialsversion2referees2approved AT mengqigong patentforamenovaleclosureversusmedicaltherapyforstrokepreventionasystematicreviewandmetaanalysisofrandomizedcontrolledtrialsversion2referees2approved AT georgebazoukis patentforamenovaleclosureversusmedicaltherapyforstrokepreventionasystematicreviewandmetaanalysisofrandomizedcontrolledtrialsversion2referees2approved AT wingtakwong patentforamenovaleclosureversusmedicaltherapyforstrokepreventionasystematicreviewandmetaanalysisofrandomizedcontrolledtrialsversion2referees2approved AT sunnyheiwong patentforamenovaleclosureversusmedicaltherapyforstrokepreventionasystematicreviewandmetaanalysisofrandomizedcontrolledtrialsversion2referees2approved AT konstantinoslampropoulos patentforamenovaleclosureversusmedicaltherapyforstrokepreventionasystematicreviewandmetaanalysisofrandomizedcontrolledtrialsversion2referees2approved AT adrianbaranchuk patentforamenovaleclosureversusmedicaltherapyforstrokepreventionasystematicreviewandmetaanalysisofrandomizedcontrolledtrialsversion2referees2approved AT lapahtse patentforamenovaleclosureversusmedicaltherapyforstrokepreventionasystematicreviewandmetaanalysisofrandomizedcontrolledtrialsversion2referees2approved AT yunlongxia patentforamenovaleclosureversusmedicaltherapyforstrokepreventionasystematicreviewandmetaanalysisofrandomizedcontrolledtrialsversion2referees2approved AT guangpingli patentforamenovaleclosureversusmedicaltherapyforstrokepreventionasystematicreviewandmetaanalysisofrandomizedcontrolledtrialsversion2referees2approved AT martincswong patentforamenovaleclosureversusmedicaltherapyforstrokepreventionasystematicreviewandmetaanalysisofrandomizedcontrolledtrialsversion2referees2approved AT yatsunchan patentforamenovaleclosureversusmedicaltherapyforstrokepreventionasystematicreviewandmetaanalysisofrandomizedcontrolledtrialsversion2referees2approved AT nanmu patentforamenovaleclosureversusmedicaltherapyforstrokepreventionasystematicreviewandmetaanalysisofrandomizedcontrolledtrialsversion2referees2approved AT meidong patentforamenovaleclosureversusmedicaltherapyforstrokepreventionasystematicreviewandmetaanalysisofrandomizedcontrolledtrialsversion2referees2approved AT tongliu patentforamenovaleclosureversusmedicaltherapyforstrokepreventionasystematicreviewandmetaanalysisofrandomizedcontrolledtrialsversion2referees2approved AT internationalhealthinformaticsstudyihisnetwork patentforamenovaleclosureversusmedicaltherapyforstrokepreventionasystematicreviewandmetaanalysisofrandomizedcontrolledtrialsversion2referees2approved |
_version_ |
1724712571872739328 |
spelling |
doaj-225f8cca90b14c80957f4de2ef6efe442020-11-25T02:56:43ZengF1000 Research LtdF1000Research2046-14022018-09-01610.12688/f1000research.13444.217114Patent foramen ovale closure versus medical therapy for stroke prevention: A systematic review and meta-analysis of randomized controlled trials [version 2; referees: 2 approved]Jenny Chi Ling Lai0Gary Tse1William K.K. Wu2Mengqi Gong3George Bazoukis4Wing Tak Wong5Sunny Hei Wong6Konstantinos Lampropoulos7Adrian Baranchuk8Lap Ah Tse9Yunlong Xia10Guangping Li11Martin C.S. Wong12Yat Sun Chan13Nan Mu14Mei Dong15Tong Liu16International Health Informatics Study (IHIS) NetworkDepartment of Medicine and Therapeutics, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong, Hong KongDepartment of Medicine and Therapeutics, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong, Hong KongDepartment of Anaesthesia and Intensive Care, State Key Laboratory of Digestive Disease, Chinese University of Hong Kong, Hong Kong, Hong KongTianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular disease, Department of Cardiology, Tianjin Institute of Cardiology, The Second Hospital of Tianjin Medical University, Tianjin, 300211, ChinaSecond Department of Cardiology, Evangelismos General Hospital of Athens, Athens, GreeceSchool of Life Sciences, Chinese University of Hong Kong, Hong Kong, Hong KongDepartment of Medicine and Therapeutics, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong, Hong KongSecond Department of Cardiology, Evangelismos General Hospital of Athens, Athens, GreeceDivision of Cardiology, Kingston General Hospital, Queen’s University, Kingston, ON, CanadaJC School of Public Health and Primary Care, Chinese University of Hong Kong, Hong Kong, Hong KongDepartment of Cardiovascular Medicine, First Affiliated Hospital of Dalian Medical University, Dalian, ChinaTianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular disease, Department of Cardiology, Tianjin Institute of Cardiology, The Second Hospital of Tianjin Medical University, Tianjin, 300211, ChinaJC School of Public Health and Primary Care, Chinese University of Hong Kong, Hong Kong, Hong KongDepartment of Medicine and Therapeutics, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong, Hong KongDepartment of Gynecology and Obstetrics, Yantai Yuhuangding Hospital Affiliated to Qingdao University, Yantai, Shandong, 264000, ChinaDepartment of Gynecology and Obstetrics, Yantai Yuhuangding Hospital Affiliated to Qingdao University, Yantai, Shandong, 264000, ChinaTianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular disease, Department of Cardiology, Tianjin Institute of Cardiology, The Second Hospital of Tianjin Medical University, Tianjin, 300211, ChinaBackground: Previous randomized trials on patent foramen ovale (PFO) closure versus medical therapy for stroke prevention were inconclusive. Recently, two new randomized trials and new findings from an extended follow-up of a previous trial have been published on this topic. We conducted a systematic review and meta-analysis of randomized trials comparing PFO closure with medical therapy for stroke prevention. Methods: PubMed and Cochrane Library were searched until 16th September 2017. The following search terms were used for PubMed: "patent foramen ovale" AND (stroke OR embolism) and "randomized" AND "Trial". For Cochrane Library, the following terms were used: "patent foramen ovale" AND "closure" AND (stroke OR embolism). Results: A total of 91 and 55 entries were retrieved from each database using our search strategy respectively, of which six studies on five trials met the inclusion criteria. This meta-analysis included 1829 patients in the PFO closure arm (mean age: 45.3 years; 54% male) and 1972 patients in the medical therapy arm (mean age: 45.1 years; 51% male). The median follow-up duration was 50 ± 30 months. When compared to medical therapy, PFO closure significantly reduced primary endpoint events with a risk ratio [RR] of 0.60 (95% CI: 0.44-0.83, P < 0.0001; I2: 15%). It also reduced stroke (RR: 0.50, 95% CI: 0.35-0.73, P < 0.0001; I2: 32%) despite increasing the risk of atrial fibrillation/flutter (RR: 1.90, 95% CI: 1.23-2.93, P < 0.01; I2: 43%). However, it did not reduce transient ischemic accident events (0.75; 95% CI: 0.51-1.10, P = 0.14; I2: 0%), all-cause bleeding (RR: 0.89; 95% CI: 0.44-1.78, P = 0.74; I2: 51%) or gastrointestinal complications (RR: 0.92; 95% CI: 0.32-2.70, P = 0.88; I2: 0%). Conclusions: PFO closure significantly reduces risk of stroke when compared to medical treatment and should therefore be considered for stroke prevention in PFO patients.https://f1000research.com/articles/6-2178/v2Cerebrovascular DiseaseCongenital Heart Disease |